Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors-Reference-Cited by-同舟云学术

Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors

Published:2024-09-04 Issue: Volume: Page:
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Chowdhury Saikat,Xiu Joanne,Ribeiro Jennifer R.^ORCID,Nicolaides Theodore,Zhang Jian,Korn W. Michael,Poorman Kelsey A.,Lenz Heinz-Josef^ORCID,Marshall John L.,Oberley Matthew J.,Sledge George W.,Spetzler David,Kopetz Scott^ORCID,Shen John Paul^ORCID

Funder

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Cancer Prevention and Research Institute of Texas

Col. Daniel Connelly Memorial Fund

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41416-024-02826-0.pdf

Reference48 articles.

1. Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233–54.

2. Atreya CE, Yaeger R, Chu E. Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches. Am Soc Clin Oncol Educ Book. 2017;37:246–56.

3. Weng J, Li S, Zhu Z, Liu Q, Zhang R, Yang Y, et al. Exploring immunotherapy in colorectal cancer. J Hematol Oncol. 2022;15:95.

4. Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, et al. Survival improvement for patients with metastatic colorectal cancer over twenty years. npj Precis Oncol. 2023;7:16.

5. Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer. 2014;134:552–62.